Aleksandra Janowiak-Majeranowska

Dr. Aleksandra Janowiak-Majeranowska

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2022 in Cancers
Verified
Journal Article
Open access
PDF file
AJAleksandra Janowiak-Majeranowska
Aleksandra Janowiak-Majeranowska
JOJakub Osowski
Jakub Osowski
Boguslaw MikaszewskiBoguslaw Mikaszewski
Boguslaw Mikaszewski
AMAlan Majeranowski
Alan Majeranowski
(1) Purpose: In this article, the authors decided to systematically review the available literature to identify potential correlations regarding secondary oral carcinoma occurring after hematological systemic treatment and oral chronic graft-versus-host disease. (2) Methods: Medline (PubMed) and Scopus (Elsevier) databases were searched, including articles from the years 2002–2022. The 33 unique results were assessed by a PRISMA flowchart, and we rejected 24 papers and included 9 articles in the review. (3) Results: The majority of patients suffered from the oral form of chronic graft-versus-host disease before the diagnosis of oral malignancy. Two common cancer sites were the tongue and buccal mucosa. The exact percentage of secondary oral carcinoma after hematopoietic stem cell transplantation could not be estimated due to a lack of data. (4) Conclusions: Every physician taking part in the follow-up of patients after hematological treatment should be aware of the possibility of secondary neoplastic disease in the oral cavity, especially in patients with oral graft-versus-host disease. Proper follow-up protocols and monitoring are needed in this patient group as the cause of these cancers appears to be multifactorial.

1 January 2024 in Contemporary Oncology
Verified
Journal Article
Open access
AJAleksandra Janowiak-Majeranowska
Aleksandra Janowiak-Majeranowska
GAGazala Abdulaziz-Opiela
Gazala Abdulaziz-Opiela
JOJakub Osowski
Jakub Osowski
BMBogusław Mikaszewski
Bogusław Mikaszewski
Platinum-based compounds used for treating hematologic malignancies can lead to various side effects. One such side effect is ototoxicity, which is characterized by permanent bilateral sensorineural hearing loss or tinnitus. Initially, it mainly affects high frequencies, but as the condition...